Five-year PHERGain results support a PET- and pathology-guided strategy that spared some women with early HER2-positive breast cancer from chemotherapy. The phase 2 trial was not designed to prove equivalence with standard treatment, and its chemotherapy-free subgroup was defined after response became known.